Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda (FACEIT-FU)
Change in Soil-transmitted Helminth Infection Intensity Following Mass Drug Administration With Ivermectin Plus Albendazole or Albendazole Alone in Ugandan Schoolchildren: a Follow-up Study to Assess Potential Drug Resistance
The goal of this prospective follow-up study nested within an open-label randomized controlled trial is to investigate the unexpectedly high prevalence of Ascaris lumbricoides infection observed 3-4 months after school-based mass drug administration with ivermectin plus albendazole (IVM-ALB) or albendazole alone (ALB) in Kisoro District, South-Western Uganda. By assessing initial treatment response and subsequent infection dynamics, the study will help clarify whether reduced drug efficacy, suboptimal treatment coverage, reinfection, or a combination of these factors may explain the previous findings.
The main questions the study aims to answer are:
- How effective are IVM-ALB and ALB against A. lumbricoides at 3 weeks, based on egg reduction and cure rates?
- How often do A. lumbricoides and other soil-transmitted helminth infections recur by 3 months?
- How effective are the treatments against Trichuris trichiura and hookworm?
- What can genetic characterization of Ascaris eggs reveal about parasite populations and potential drug resistance markers?
The study will enrol 450 pupils aged 5-14 years from three primary schools, which participated in the previous mass drug administration evaluation. In each school, 150 pupils will be randomly assigned equally to receive a single oral dose of:
- ivermectin (200 µg/kg) plus albendazole (400 mg); or
- albendazole (400 mg) alone.
Each treatment arm will include 225 pupils overall. Children will be included regardless of baseline infection status, following parental/guardian informed consent and child assent. Other pupils will receive routine albendazole under national deworming guidelines.
Stool samples will be collected before treatment and at 3 weeks and 3 months. Duplicate Kato-Katz thick smears will quantify A. lumbricoides, T. trichiura and hookworm eggs. The primary outcome is the arithmetic mean egg reduction rate for A. lumbricoides at 3 weeks. Secondary outcomes include cure rates at 3 weeks, reinfection rates at 3 months, egg reduction and cure rates for T. trichiura and hookworm, and genetic characterization of Ascaris populations and potential resistance markers. Adverse events will be recorded through passive safety monitoring.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Jennifer Keiser, Prof.
- Numéro de téléphone: +41 61 284 82 18
- E-mail: jennifer.keiser@swisstph.ch
Sauvegarde des contacts de l'étude
- Nom: Peter Steinmann, Dr.
- Numéro de téléphone: +41 61 284 82 29
- E-mail: peter.steinmann@swisstph.ch
Lieux d'étude
-
-
-
Kampala, Ouganda
- Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health
-
Contact:
- Prudence Beinamaryo, Dr.
- Numéro de téléphone: +256-789-548-930
- E-mail: prudenceb13@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Informed consent provided by parent/guardian and assent provided by pupil
- School-aged children (5-14 years) enrolled in the respective study schools
- Able and willing to provide a stool sample before and 3 weeks and 3 months post-treatment
Exclusion Criteria:
- Presence or signs of major systemic illness
- Recent use of anthelmintic drugs in the 4 weeks before treatment
- Known allergy to study medication (i.e. benzimidazoles or ivermectin)
- Participation in other clinical trials
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: IVM (200 µg/kg) + ALB (400 mg)
A single tablet of albendazole (400mg) plus 200 µg/kg of ivermectin, provided as single oral dose. |
Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
Autres noms:
World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
Autres noms:
|
|
Comparateur actif: ALB (400mg)
A single tablet of albendazole (400mg), provided as single oral dose. |
Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Egg Reduction Rates (ERRs) for A. lumbricoides infection at 3 weeks post-treatment
Délai: 3 weeks after treatment
|
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the duplicate Kato-Katz thick smears and multiplying this number by a factor of twelve. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment. Egg reduction for A. lumbricoides infection will then be calculated as change in egg counts from baseline to 3 weeks post-treatment. |
3 weeks after treatment
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants A. lumbricoides egg negative at 3 weeks post-treatment (cured)
Délai: 3 weeks after treatment
|
The conversion from being egg positive pre-treatment to egg negative post-treatment, or cure rate (CR). |
3 weeks after treatment
|
|
Number of participants egg negative at 3 weeks with soil-transmitted helminth infections 3 months post-treatment (reinfected)
Délai: 3 months after treatment
|
Number of participants that converted from egg negative with Ascaris lumbricoides, Trichuris trichiura and/or hookworm infections at 3 weeks post-treatment to egg positive after 3 months. |
3 months after treatment
|
|
Number of participants with concomitant soil-transmitted helminth infections egg negative at 3 weeks post-treatment (cured)
Délai: 3 weeks after treatment
|
Number of participants that converted from egg positive with Trichuris trichiura and/or hookworm infections to egg negative after 3 weeks. |
3 weeks after treatment
|
|
Egg-reduction Rates (ERRs) against concomitant soil-transmitted helminth infections
Délai: 3 weeks after treatment
|
Percent change in arithmetic and geometric mean eggs per gram of stool from before to after treatment. ERRs will be calculated for Trichuris trichiura and hookworm infections as described in outcome 1. |
3 weeks after treatment
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Jennifer Keiser, Prof., Swiss Tropical & Public Health Institute
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Infections
- Maladies parasitaires
- Infections sécrétoires
- Infections à nématodes
- Helminthiase
- Infections à ascarides
- Ascaridiase
- Produits chimiques organiques
- Composés hétérocycliques
- Benzimidazoles
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Acides, acyclique
- Acides carboxyliques
- Macrolides
- Lactones
- Polycétides
- Carbamates
- Ivermectine
- Albendazole
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2283FU
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
There is a data sharing agreement between Swiss TPH and Uganda MoH in place. Data may be shared with other researchers upon request.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .